London, 29 July 2011 — ONET TECHNOLOGIES UK Ltd (OTUK) has agreed to manufacture specialised hot cells for the production and commercialization of ALPHARADIN (radium-223 chloride). Developed by ALGETA SAS of Norway, ALPHARADIN is a highly targeted alpha-pharmaceutical, currently under clinical evaluation, which is intended to improve survival in patients with bone metastases from advanced cancer.
Andrew Kay, the President and CEO of ALGETA SAS of Norway, says: “We are delighted that ONET and ALGETA are working together on the final stages of the commercial manufacturing process for ALPHARADIN to ensure that the product will be available to cancer patients with bone metastases, pending approval for this first-in-class alpha-pharmaceutical.”
This contract is a clear milestone in the development of ONET TECHNOLOGIES UK Ltd (OTUK), the British subsidiary of ONET TECHNOLOGIES, and complements its strategy for expansion in the radiopharmaceutical market, to which ONET TECHNOLOGIES will bring its extensive experience.
ALPHARADIN is the lead product developed by ALGETA ASA, which is based in Oslo (Norway). The Scandinavian firm is one of Europe’s leading cancer-research companies and specialises in targeted therapies based on its alpha-pharmaceutical technology. ALGETA selected OTUK for the final stages of the process, regarding the supply of a high-capacity, state-of-the-art production line for the manufacturing of sterilized ready-to-use products.
OTUK’s overall scope of work for the production line includes design, supply, installation and testing. The contract is similar to work undertaken by ONET TECHNOLOGIES for other clients in this sector, and relies on OTUK’s experience and expertise in the radiopharmaceutical market.
About ALGETA SAS
ALGETA SAS, which is headquartered in Oslo (Norway), is an oncology company developing targeted therapies for cancer patients, which are based on its alpha-pharmaceutical platform.
ALGETA’s lead product, based on radium-223, is a first-in-class, highly targeted alpha-pharmaceutical under clinical evaluation aimed at improving survival in patients with bone metastases from advanced cancer. It has been developed in partnership with Bayer Schering Pharma AG, a major pharmaceutical company, and is in a global Phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from prostate cancer.
For more information about ALGETA SAS, please go to: http://www.algeta.com/
About ONET TECHNOLOGIES
ONET TECHNOLOGIES is part of ONET group, which is headquartered in Marseille (in south-eastern France). ONET TECHNOLOGIES provides advanced solutions in the civil nuclear industry, and assists players seeking high-tech solutions that will contribute to the responsible development of nuclear technology in its various applications, including in the medical field.
ONET TECHNOLOGIES has been a key player in the civil nuclear industry for over 30 years. Today, ONET TECHNOLOGIES has a workforce of more than 2,300, including 600 engineers and experts, as well as nearly 1,700 technicians and specialist operators. The company’s turnover is of €225 million.
ONET TECHNOLOGIES supports its customers throughout the entire life cycle of their nuclear facilities: ONET TECHNOLOGIES is France’s market leader in the dismantling of power reactors and the management of radioactive waste.
ONET TECHNOLOGIES is also a leading manufacturing concern. Since 2001, ONET TECHNOLOGIES has sought to set up partnerships with major international players in engineering and manufacturing, the most noteworthy of which is its alliance with MITSUBISHI HEAVY INDUSTRIES of Japan.
ONET TECHNOLOGIES has underpinned its international expansion through the setting-up of various subsidiaries, which include ONET TECHNOLOGIES UK, ONET TECHNOLOGIES BULGARIA, ONET TECHNOLOGIES ROMANIA, ONET TECHNOLOGIES ITALIA and ONET TECHNOLOGIES INDIA.
ONET TECHNOLOGIES is also focused on innovations for the future, and is bringing its expertise to projects such as ITER, experimental reactors and Generation IV.
Finally, ONET TECHNOLOGIES has developed solutions with a range of applications in the medical field, including cancer research and treatment.
For more information about ONET TECHNOLOGIES, please go to: http://www.onet-technologies.com/en/
For further information, please contact :
Quote ref. : FTPB3614
Ms Katherine WOODS - Press Officer
UBIFRANCE Press Office in London
Tel: +44 (0) 207 024 3640
View other press releases at :